Literature DB >> 7104187

Bioavailability of labetalol increases with age.

J G Kelly, K McGarry, K O'Malley, E T O'Brien.   

Abstract

The antihypertensive drug labetalol was administered orally and intravenously to ten hypertensive patients aged between 28 and 75 years. There was a significant increase with age in both bioavailability and half-life of labetalol. Clearance tended to be lower in the elderly subjects. First pass metabolism results in variable oral bioavailability of labetalol which is greater in the elderly and this should be borne in mind when using the drug in this age group.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7104187      PMCID： PMC1427732          DOI： 10.1111/j.1365-2125.1982.tb01983.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  5 in total

Review 1.  Altered hepatic blood flow and drug disposition.

Authors:  A S Nies; D G Shand; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

2.  Rate of onset of hypotensive response with oral labetalol [proceedings].

Authors:  A M Breckenridge; C M Macnee; N L Orme; D A Richards; M J Sterlin
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

Review 3.  Drug kinetics and hepatic blood flow.

Authors:  C F George
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

4.  Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects.

Authors:  J J McNeil; A E Anderson; W J Louis; D J Morgan
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

5.  Radioreceptor assay for labetalol.

Authors:  J G Kelly; K McGarry; K O'Malley
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335
  5 in total
  14 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

4.  Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment.

Authors:  M Larsson; S Landahl; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 5.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

Review 6.  Clinical pharmacokinetics of labetalol.

Authors:  J J McNeil; W J Louis
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 7.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

8.  Hepatic drug clearance: the effect of age using indocyanine green as a model compound.

Authors:  H A Wynne; J Goudevenos; M D Rawlins; O F James; P C Adams; K W Woodhouse
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.

Authors:  R Donnelly; G J Macphee
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 10.  Pharmacology of combined alpha-beta-blockade. I.

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Drugs       Date:  1984       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.